Gubra A/S Logo

Gubra A/S

CRO & biotech accelerating peptide drug discovery for metabolic and fibrotic diseases.

GUBRA | CO

Overview

Corporate Details

ISIN(s):
DK0062266474
LEI:
254900T17RRFZONO6W53
Country:
Denmark
Address:
Hørsholm Kongevej 11 B, 2970 Hørsholm
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Gubra A/S is a specialized preclinical Contract Research Organization (CRO) and biotechnology company focused on peptide-based drug discovery for metabolic and fibrotic diseases, such as obesity, diabetes, and MASH. Founded in 2008, the company operates through two primary business areas: CRO Services, providing advanced preclinical research to accelerate partners' drug development, and Discovery & Partnerships, which develops its own pipeline of next-generation peptide therapeutics. Gubra leverages its expertise in in vivo pharmacology and peptide chemistry to streamline and advance early-stage drug development for its clients and internal projects.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Gubra A/S filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Gubra A/S

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Gubra A/S via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Oryzon Genomics S.A. Logo
Develops epigenetic-based medicines for cancer and central nervous system disorders.
Spain ORY
OSCOTECInc. Logo
A clinical-stage drug discovery company developing innovative medicines for unmet needs.
South Korea 039200
OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan 4766
Passage BIO, Inc. Logo
Developing genetic medicines for severe CNS and neurodegenerative disorders.
United States of America PASG
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway PCIB
PC İLETİŞİM VE MEDYA HİZMETLERİ SANAYİ TİCARET A.Ş. Logo
Integrated media group providing data-driven advertising and media solutions for global brands.
Türkiye PCILT
PDS Biotechnology Corp Logo
Developing T-cell activating immunotherapies for cancer and infectious diseases.
United States of America PDSB
Peers Co.,Ltd. Logo
Accelerating tech adoption with consulting, HR services, and proprietary IT/AI solutions.
Japan 7066

Talk to a Data Expert

Have a question? We'll get back to you promptly.